Bimodal Anti-viral Combination Therapy for SARS-CoV-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, particularly those targeting SARS-COV-2, face limitations due to the toxic and lethal effects of the Pathogenic Host Response (PHR), which causes inflammation-induced lung injury and organ failure, and existing anti-viral drugs have shown limited efficacy.
Innovation Solution
A bimodal combinatorial therapy combining anti-PHR components with anti-viral agents, such as β-cyclodextrin-modified rutin and ivermectin, to modulate the Pathogenic Host Response and inhibit SARS-COV-2 replication, demonstrated to enhance survival rates and reduce morbidity in human ACE2 transgenic mouse models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-viral drugs are used to treat SARS-COV-2 infection, then viral replication is targeted, but treatment efficacy is limited
Solution Approach 1:
The patent combines anti-viral agents (e.g., remdesivir, lopinavir/ritonavir) with anti-inflammatory agents (e.g., dexamethasone, hydroxychloroquine) into a single pharmaceutical composition. This merging of two therapeutic modalities addresses both viral replication and pathological inflammation simultaneously, thereby improving overall treatment efficacy while maintaining targeted anti-viral activity.
2Object-affected harmful factors
If anti-inflammatory treatment is applied to reduce Pathogenic Host Response, then morbidity and mortality are reduced, but viral replication control may be compromised
Solution Approach 1:
The patent integrates anti-inflammatory agents that suppress the Pathogenic Host Response with anti-viral agents that inhibit viral replication within the same pharmaceutical composition. This combination ensures that both harmful inflammatory effects and viral replication are controlled simultaneously, maintaining reliable anti-viral activity while reducing morbidity and mortality associated with cytokine storm.
Data Source
AI summary
Pharmaceutical compositions, kits, and methods are disclosed for use in treating or reducing the occurrence of a viral infection in a patient. The compositions, kits, and methods utilize at least one anti-Pathogenic Host Response (anti-PHR) agent, either alone or in combination with at least one anti-viral agent.